High-dose Chemotherapy With Rituximab for Adults With Aggressive Large B-cell Lymphoma

• Status: Completed
• Trial end date: 2009-06-01
• Target enrollment: 0
• Participant gender: All

Summary

A prospective pilot trial was proposed to patients with DLBCL, with IH or high adjusted IPI, up to the age of 60 y.o. This program consisted of 2 courses of high-dose R-CHOP-like regimen, followed by a course of high-dose methotrexate with cytarabin. For patients who achieved at least a PR, ASCT started with a BEAM regimen.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nantes University Hospital
• Collaborators: French Innovative Leukemia Organisation; Hoffmann-La Roche
• Treatments: Rituximab

Criteria

Inclusion Criteria:

• Age 18 to 60 y.o

• Aggressive Large B-Cell Lymphoma (CD20+)

• Ann Arbor stage III, IV

• IH or high adjusted IPI

• signed inform consent

Exclusion Criteria:

• Age < 18 ou > 60 y.o

• other type of lymphoma

• serology VIH +

• other neoplasms apart from basal cell carcinoma or situ carcinoma